OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Consensus Rating of "Moderate Buy" from Analysts

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $35.83.

KIDS has been the subject of several research reports. Truist Financial reduced their price objective on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a report on Friday, April 11th. Wall Street Zen raised OrthoPediatrics from a "sell" rating to a "hold" rating in a research note on Friday. Lake Street Capital initiated coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 price objective on the stock. Stifel Nicolaus lowered their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, March 5th. Finally, Piper Sandler dropped their target price on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Thursday, May 8th.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS traded up $0.11 during midday trading on Friday, hitting $21.48. The company had a trading volume of 73,750 shares, compared to its average volume of 198,231. The firm has a market capitalization of $521.75 million, a price-to-earnings ratio of -12.27 and a beta of 1.08. OrthoPediatrics has a twelve month low of $19.52 and a twelve month high of $35.99. The business has a 50-day simple moving average of $21.41 and a two-hundred day simple moving average of $23.08. The company has a quick ratio of 2.99, a current ratio of 6.19 and a debt-to-equity ratio of 0.21.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The company had revenue of $52.41 million during the quarter, compared to analysts' expectations of $51.68 million. OrthoPediatrics had a negative net margin of 19.15% and a negative return on equity of 7.03%. Equities research analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current year.

Institutional Trading of OrthoPediatrics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. KLP Kapitalforvaltning AS acquired a new position in OrthoPediatrics in the 4th quarter valued at about $79,000. Wells Fargo & Company MN boosted its stake in shares of OrthoPediatrics by 31.1% during the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock worth $228,000 after purchasing an additional 2,338 shares during the last quarter. PDT Partners LLC purchased a new stake in shares of OrthoPediatrics during the first quarter worth about $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock valued at $246,000 after buying an additional 645 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of OrthoPediatrics by 4,618.2% in the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company's stock valued at $261,000 after buying an additional 10,391 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.